

Index

- Abelson murine leukemia virus, 288
N-Acetylgalactosaminyltransferase, 362, 367, 371, 372
N-Acetylglucosaminepyrophosphoryldolichol, 364
Acyclovir, 11, 16, 17, 18
Adenine arabinoside, 33
Adenovirus
 transcription of, 51
 transforming potential of, 258, 269, 279–280, 283–284, 286
Alkaline exonuclease activity, in HSV infections, 61
Alphaherpesvirinae, 105
Amino acid analogs, transcription and, 53
Amino acid sequences, of HSV glycoproteins, 319
Ammonium chloride, glycosylation inhibition by, 375, 376, 377
Antibody(ies)
 HSV
 in cervical cancer, 30–31, 32, 245–247, 251
 neutralizing, 3, 5–6, 331–333
 in sexual transmission, 10–11
 monoclonal: *see* Monoclonal antibodies
 Antibody assay type-specific, 5
 Antigens
 in latent HSV infections, 197
 tumor-associated, 31–32, 245–248, 250, 251
 Arginine, in capsid assembly, 148
 Aujeszky's disease, 161–163
 Autonomic nervous system, HSV infections of, 208
 Avian erythroblastosis virus, 284
 Avian leukosis virus, 268
 Avian lymphoid leukosis virus, 284, 285
 Bell's palsy, 28, 208
 Benzhydrazone, glycosylation inhibition by, 374–375
 Biological markers
 cotransfection of, 276
 of HSV transcripts, 45–47, 60, 62–63
 Blot hybridization
 of HSV DNA sequences, 263–264, 273
 of HSV RNA transcripts, 49, 52, 54–55, 56–57
 of PRV, 159
 Bovine mammillitis virus, 111
 Brain, HSV infection of, 3, 7, 24–28; *see also* Central nervous system
 Calcium phosphate precipitation technique, 276, 298–299
 Cancer
 CMV and, 257
 Epstein–Barr virus and, 257
 HSV and, 241, 257
 See also Oncogenic transforming potential; names of specific cancers
 Capsids
 of HSV
 assembly of, 148
 proteins of, 68–70
 of PRV, 107–109
 assembly of, 148–151
 Cats, PRV infection in, 122
 Cattle, PRV infection in, 161, 162

- Cell culture, oncogenic transformation in, 259–261
- Cellular stress protein, 72
- Central nervous system, HSV infections of, 24–27
- latency of, 176, 179–180
- Cervical cancer
- epidemiology of, 30–32, 243–245
- HSV and, 29–33, 241
- HSV-1 and, 70–71
- HSV-2 and, 30, 241–255
- antigens of, 32–33, 245–248, 250, 251
- DNA sequences of, 248–250, 251
- risk estimation for, 242–245
- risk factors of, 241, 244–245
- seroepidemiologic surveys of, 243–245
- papillomaviruses and, 251, 252
- Chemotherapy, antiviral, 4
- Children
- HSV excretion by, 16
- HSV infections in, 4, 5–7
- CMV: *see* Cytomegalovirus(es)
- Cocultivation method, of HSV, 178
- C3b receptors, 340
- Cyclohexamide
- HSV RNA transcripts and, 53
- PRV protein synthesis and, 159
- Cyclophosphamide
- HSV reactivation by, 203
- latent HSV infections and, 191
- Cytomegalovirus(es)
- cancer and, 257
- DNA, 292–293
- genome size, 289
- glycoproteins specified by, 383–402
- antigenically distinct, 387
- characteristics of, 391, 393–394
- in dense bodies, 384–386
- electrophoretic mobility of, 396–398
- electrophoretic properties of, 385–386, 387–388
- gA forms, 390–400
- monoclonal antibody characterization of, 386–392
- in plasma membrane, 384–386
- polymorphism of, 392–400
- purification of, 390–392
- synthesis and processing of, 384, 392–400
- in virions, 384–386
- host–virus interactions of, 289–290
- lytic cycle of, 290
- protein synthesis and, 296–298
- mRNA splicing in, 48
- Cytomegalovirus(es) (*cont.*)
- transforming potential of, 257–258, 289–302
- DNA sequences and, 292–300
- virion content, 383
- Cytosine arabinoside, 52
- Cytotoxicity, cell-mediated, 219
- Darier's disease, 20
- Defective genomes, 142
- Defective-interfering particles, 195
- Defective virions, 289
- Degenerative disease, 28
- Dense bodies, 384–386
- Deoxycytidylic acid, 137
- 2-Deoxy-D-glucose, as glycosylation inhibitor, 333, 374, 377
- Deoxypyrimidine triphosphatase, 65–66
- DNA
- CMV, 292–293
- HSV
- coding capacity of, 373
- fragment patterns of, 13–14
- latency and, 191–192
- in oncogenic transformation, 262, 263–266, 267, 268, 269–279, 280–282, 284–288, 289
- HSV-2
- in cervical cancer cells, 248–250, 251
- restriction endonuclease analysis of, 13–14, 265, 269–270
- PRV
- cleavage of concatemeric forms, 151–153
- defective genomes of, 142
- functional identity of, 116
- heterogeneity of, 113
- homology of, 112
- mutants, 156–157
- properties of, 111–112, 138–141
- replication origins in, 141–143
- restriction endonuclease analysis of, 111, 113–118
- strain variability of, 116, 118
- DNA polymerase
- in HSV infection diagnosis, 27
- mapping of, 64–65
- PRV-induced, 137
- mutator activity of, 287
- DNA synthesis
- in HSV-infected cells, 61, 64–66
- inhibition of, 52, 160
- protein synthesis and, 130–131, 132

- DNA synthesis (*cont.*)
 in PRV-infected cells, 122–123, 125, 138–141
 inhibition of, 160
 mode of, 143–144
See also Transcription
 DNase, 28, 138
- Early and late PRV proteins, 132
 Early and late PRV RNA, 122–123, 125, 127–129
 Eczema herpeticum, 29
 EHV-1: *see* Equine abortion virus
 Embryonated eggs, PRV infections in, 122
 Embryonic cells, transformation assays of, 259–260
 Encephalitis, HSV-associated, 3, 7, 24–27
 latency and, 208–209
 pathogenesis of, 25–26
 restriction endonuclease analysis of, 29
 Endo- β -*N*-acetylglucosaminidase H, 322, 359, 364
 Endocytosis, 334–335
 Endonuclease restriction analysis: *see* Restriction endonuclease analysis
 Enzyme(s)
 of HSV, 197
 of PRV, 137–138
See also names of specific enzymes
 Enzyme-linked immunosorbent assay, 5
 Epidemics, of HSV infections, 28–29
 Epidemiologic surveys
 of cervical cancer, 242–245
 of HSV infections, 5, 6
 Epstein–Barr virus
 cancer and, 257
 mRNA of, 48, 50
 Equine abortion virus
 cross-reactivity of, 111
 transcription in, 51
 Equine herpesvirus, 52
 Eye, herpes infections of, 2, 18–20
- Fatty acylation, 325, 329
 Fc receptors, 194–195, 202, 335, 339
 Ferret, PRV infections in, 122
 Fucose/glucosamine ratio, of HSV-1 glycoproteins, 359
 Fusion, virus-induced, 120–121, 340–345, 376–378
See also polycaryocytes
- Galactosyltransferase, 372
- Ganglia, latent HSV infections in, 12–13, 176–180
 antigens in, 197
 defective-interfering particles in, 195
 dynamic state of, 195, 196
 enzymes of, 197
 establishment of, 182–198
 Fc receptors of, 194–195
 genome in, 191–192, 196
 in latently infected cells, 188–190
 in neurons, 189–195
 peripheral viral growth and, 185–188
 reactivation of, 198–224
 mRNA in, 197–198
 spread of, 182–185
 static state of HSV in, 195, 198
 thymidine kinase gene expression in, 193–194
 viral function and, 195–198, 199
- Genetic complementation analysis
 of HSV, 269
 of PRV, 154–155
- Genetic drift, 144
- Genital herpetic infections
 complications of, 8–9
 cytopathologic screening for, 10
 disease expression and, 10–11
 incidence of, 9–10
 in pregnant women, 16, 22–23
 recurrent, 14–16
 treatment of, 16–18
 symptoms of, 8
 treatment of, 11–12, 16–18
- Genome
 CMV, 289
 HSV
 latency and, 191–192, 196, 203–204
 plasmidlike state of, 191–192
 sequence homology of, 160–161, 281–282
 PRV, 111–119
 functional identity of, 116
 isomerization of, 146–148, 149
 mapping of, 115–116, 117, 157–158
 organization of, 154–158
 restriction endonuclease analysis of, 115–116, 117
 RNA transcription patterns of, 122–124
 sequence homology of, 147, 160–161
 sequence identity maintenance of, 144–146
 size and base composition of, 111

Genome (*cont.*)PRV (*cont.*)

- strain variability of, 116, 118
- structure of, 112–115
- vaccine strains of, 118–119

See also DNA

Genomic fragment transformation

- by HSV-1, 272–274
- by HSV-2, 274–281

Gingivostomatitis, 3, 6, 11

Glycans

- addition sites of, 320–321
- assembly of, 362–366
- high-mannose, 361–363, 367–368
- infectivity and, 333, 375–376
- N-linked, 320–321, 322–323, 359, 361–368
- O-linked, 323–324, 362–363
- of pgC and gC, 368–371
- sialylated, 363, 366, 369
- structure of, 362–363
- sulfation of, 359
- synthesis pathway of, 361–363
- virion egress and, 376

Glycoproteins

- of CMV, 383–402
 - antigenically distinct, 387
 - characteristics of, 391, 393–394
 - in dense bodies, 384–386
 - electrophoretic mobility of, 396–398
 - electrophoretic properties of, 385–386, 387–388
 - gA forms, 390–400
 - monoclonal antibody characterization of, 386–392
 - in plasma membrane, 384–386
 - polymorphism of, 392–400
 - purification of, 390–392
 - synthesis and processing of, 392–400
 - in virion, 384–386
- excreted, 136–137
- of HSV, 315–356
 - fatty acylation of, 325
 - functional relatedness of, 345
 - genetic loci of, 315–319
 - host cell fusion and, 340–345
 - in host cell penetration, 334–336
 - intermolecular interactions of, 325–326
 - intracellular locations for, 328–331
 - mapping of, 316–318
 - N-linked glycans of, 320–321, 322–323
 - nomenclature of, 267, 345–347
 - O-linked glycans of, 323–324, 362–363

Glycoproteins (*cont.*)of HSV (*cont.*)

- orientation within, 321–322
 - polypeptide moieties of, 319–322
 - prosthetic groups of, 322–325
 - receptor expression and, 338–340
 - regulation of synthesis of, 327–328
 - signal sequences of, 319–320
 - structural genes of, 315–326
 - structure of, 319–325
 - sulfation of, 324–325
 - synthesis and processing of, 326–331
 - transcription of, 66–68
 - virion adsorption and, 334
 - virion envelopment and egress and, 336–338
 - virion infectivity and, 331–336
 - of HSV-1, 357–382
 - forms, 358–359
 - fucose/glucosamine ratio of, 359
 - properties of, 359, 360
 - synthesis pathway of, 361–363
 - of PRV, 136–137
 - monoclonal antibody neutralization of, 110–111
 - of Sindbis virus, 357, 361, 362
- Glycosylation
- cell fusion and, 376–378
 - general pathway of, 361–363
 - Golgi apparatus in, 361–363, 369
 - host-cell dependence of, 371–374
 - infectivity and, 375–376
 - inhibitor of, 323, 329–330
 - by ammonium chloride, 375, 376
 - by benzhydrazone, 374–375
 - by 2-deoxy-D-glucose, 374, 377
 - by monensin, 375–376
 - by tunicamycin, 374, 377
 - N-linked glycans in, 361–368
 - relationship between N- and O-forms of, 367–368
 - sialic acid in, 363, 366, 367, 369
 - site specificity of, 370–371
- Glycosyltransferases, 371–372
- Golgi apparatus, in glycosylation, 361–362, 369
- Gonorrhea, 9
- Guinea pigs
 - latent HSV infection in, 176, 179, 181, 209
 - PRV infection in, 122
- Hamster, PRV infection in, 122
- Hamster embryo fibroblasts, oncogenic transformation in, 259

- Herpes gladiatorum, 20
- Herpes keratitis, 2
- Herpes labialis, 2
 recurrent, 14–16, 219
 treatment of, 16
- Herpes genitalis, 7–11
 recurrent, 14–16
- Herpes simplex virus
- antibodies
 - in cervical cancer, 30–31, 32, 245–247, 251
 - sexual transmission and, 10–11
 - symptomatic infection and, 7
 - antigenic strain differences of, 3
 - antigens
 - in latent infection, 197
 - tumor-associated, 31–32, 245–248, 250, 251
 - capsids
 - assembly of, 148
 - proteins of, 68–70
 - cervical cancer and, 29–33, 241
 - complementation analysis of, 269
 - control of, 4
 - cross-reactivity of, 4–5
 - DNA
 - coding capacity of, 373
 - fragment patterns of, 13–14
 - latency and, 191–192
 - in oncogenic transformation, 262, 263–266, 267, 268, 269–279, 280–282, 284–288, 289
 - epidemic disease and, 28–29
 - epidemiology of, 1–44
 - demographic factors in, 5–7
 - descriptive, 3–12
 - historical background of, 2–3
 - serologic surveys, 5–6
 - of specific diseases, 18–29
 - techniques, 5, 10
 - eye infections caused by, 2, 18–20
 - genital infections caused by
 - complications of, 8–9
 - cytopathologic screening for, 10
 - disease expression of, 10–11
 - epidemiology of, 7–11
 - incidence of, 9–10
 - in pregnant women, 16, 22–23
 - recurrent, 16–18
 - symptoms of, 8
 - treatment of, 11–12, 16–18
 - genome
 - latency and, 191–192, 196, 203–204
 - plasmidlike state of, 191–192
 - sequence homology of, 160–161
- Herpes simplex virus (*cont.*)
- glycoproteins, 315–356
 - fatty acylation of, 325
 - functional relatedness of, 345
 - genetic loci of, 315–319
 - host cell fusion by, 340–345
 - in host cell penetration, 334–336
 - intermolecular interactions of, 325–326
 - intracellular locations for, 328–331
 - mapping of, 316–318
 - N-linked glycans of, 320–321, 322–323
 - nomenclature of, 267, 345–347
 - O-linked glycans of, 323–324, 362–363
 - orientation within, 321–322
 - polypeptide moieties of, 319–322
 - prosthetic groups of, 322–325
 - receptor expression and, 338–340
 - regulation of, 327–328
 - signal sequences of, 319–320
 - structural genes of, 315–326
 - structures of, 319–325
 - sulfation of, 324–325
 - synthesis and processing of, 326–331
 - transcription of, 66–68
 - virion adsorption and, 334
 - virion envelopment and egress and, 336–338
 - virion infectivity and, 331–336
 - glycosyltransferase-defective, 371–372
 - host cell interactions, 257
 - in immunocompromised host, 20–21
 - latent infections of, 12–14, 175–240
 - animal models of, 176
 - antigens in, 197
 - cell models of, 72
 - in central nervous system, 176, 179–180
 - defective-interfering particles in, 195
 - dynamic state of, 195, 196
 - enzymes in, 197
 - establishment in ganglia of, 182–198
 - evolutionary aspects of, 224–225
 - extraneural, 180–182
 - Fc receptors and, 194–195
 - genome in, 191–192, 196, 203–204
 - in latently infected cell, 188–190
 - in neurons, 189–195, 203–205
 - in peripheral nervous system, 176–179
 - recurrence and, 175
 - mRNA in, 197–198
 - shedding and, 207
 - sites of, 176–182
 - static state of, 195, 198

- Herpes simplex virus (*cont.*)
- latent infections of (*cont.*)
 - thymidine kinase gene expression and, 193–194
 - viral function, expression in, 195–198, 199
 - mutator activity of, 287
 - neonatal infections, 21–24
 - incidence of, 21–22
 - symptoms of, 23–24
 - transmission of, 16, 22–23, 29
 - nervous system infections, 3, 7, 24–28, 176–180
 - neutralizing antibodies, 3, 5–6, 331–333
 - oncogenic transforming potential of, 257–289, 300–302
 - antigenic markers for, 268
 - in cell culture, 258–261
 - DNA sequences in, 263–266, 267, 268, 269–279, 280–282, 284–288, 289
 - genome homology in, 281–282
 - genomic fragment transformation, 272–281
 - “hit-and-run” mechanism of, 277–278, 287
 - protein expression and, 266–270
 - thymidine kinase in, 262, 263–266
 - transformation frequency, 261–262
 - transformation mechanisms, 283–289
 - of virions, 258–261
 - oral infections, 6–7
 - peripheral lesion recurrence, 209–224
 - animal models of, 210–212, 213
 - clinical problem of, 209
 - host factors in, 217–223
 - sites of, 212, 214–217
 - viral factors in, 223–224
 - reactivation of, 198–224
 - autonomic nervous system disorders, 208
 - encephalitis, 208–209
 - host factors in, 201–205
 - immune mechanisms of, 202–203
 - neuron in, 206–207
 - psychiatric disorders, 208
 - results of, 207–224
 - viral factors in, 205–206
 - recurrent infections
 - incidence of, 4
 - reinfection vs., 12–18
 - therapy and, 11–12
 - replication sites of, 7
 - mRNA
 - general properties of, 48–50
- Herpes simplex virus (*cont.*)
- mRNA (*cont.*)
 - host cell response, 53–54
 - in latency, 197–198
 - mapping of, 46
 - shedding of, 6–7, 180–181, 207
 - skin infections, 3, 20, 180, 181, 214–217
 - transcripts of, 45–104
 - analysis of, 55–60
 - biological markers for, 45–47, 60, 62–63
 - blot surveys of, 49, 52, 54–55, 56–57
 - for DNA replication functions, 61, 64–66
 - of α genes, 60–61
 - of glycoproteins, 66–68
 - interior promoters of, 88–89
 - latency and, 71–72
 - localization of, 54–55, 274
 - of morphological transformation genes, 70–71
 - multiple promoters of, 86–88
 - of related protein functions, 89–90
 - of specific genes, 60–72
 - splicing and, 89
 - of structural proteins, 68–70
 - termination of, 86, 88
 - of “typical” genes, 84–86
 - transmission of, 3–4, 7
 - neonatal, 16, 22–23, 29
 - nosocomial, 22, 29
 - sexual, 8, 10
 - treatment of, 11–12, 16–18
 - resistant strains and, 18
 - in trigeminal ganglion, 72, 176–177, 178, 180, 182, 196, 197
 - virions of
 - adsorption by, 334
 - defective, 289
 - egress of, 337–338
 - endocytosis of, 334–335
 - envelopment of, 336–337
 - infectivity of, 331–336
 - oncogenic transforming potential of, 258–261, 289
 - in protein synthesis inhibition, 53–54
- Herpes simplex virus-2
- cancer and, 257
 - cervical, 70–71
 - characteristics of, 3
 - cross-reactivity of, 111
 - epidemiology of, 4–7
 - genital infections, 7–11

- Herpes simplex virus-2 (*cont.*)
 glycans of, 375–376
 addition sites of, 320–321
 assembly of, 363–366
 high-mannose, 361–362
 infectivity and, 333, 375–376
 N-linked, 320–321, 322–323, 359, 363–366
 O-linked, 323–324, 362–363
 of pgC and gC, 368–371
 sialylated, 363, 366, 369
 structure of, 361–363
 sulfation of, 359
 synthesis pathway of, 361–363
 virion egress and, 376
 glycoproteins of, 357–382
 forms, 358–359
 fucose/glucosamine ratio, 359
 properties of, 359, 360
 synthesis pathway of, 361–363
 glycosylation in
 benzhydrazone inhibition of, 374–375
 cell fusion and, 376–378
 general pathway of, 361–363
 host cell dependence of, 373–374
 relationship between *N*- and *O*- forms of, 367–368
 site specificity of, 370–371
 infection site of, 4
 lytic function of, 281
 oncogenic transforming potential of, 272–274
 recurrent infections, 14–16
 treatment of, 16
 mRNA, 48
 analysis of, 55–57
 high-resolution mapping of, 57–60
 Syn mutations of, 341–345
 transcription units of, 72–86
- Herpes simplex virus-2
 cervical cancer and, 30–33, 241–255
 antigens, 245–248, 250, 251
 DNA sequences, 248–250, 251
 epidemiologic surveys of, 243–245
 risk estimation for, 242–245
 risk factors for, 241, 244–245
 cross-reactivity of, 111
 DNA restriction analysis, 265, 269–270
 genital infections, 7–11
 recurrent, 17–18
 hybridization kinetic analysis of, 270, 271
 infection site of, 4
 lytic function of, 281
- Herpes simplex virus-2 (*cont.*)
 oncogenic transforming potential of, 259–261
 genomic fragment transformation, 274–281
 Herpes zoster, *see* Varicella zoster virus
 Herpesviruses, as oncogenic viruses, 257–258
- Hospitals, HSV infections in, 22, 29
 HSV-1: *see* Herpes simplex virus-1
 HSV-2: *see* Herpes simplex virus-2
 Human cells, transformation assays of, 260
 Human cytomegalovirus: *see*
 Cytomegalovirus(es)
 Hybridization kinetic analysis, of HSV-2, 270, 271
 Hydroxanthine-guanine
 phosphonoribosyltransferase gene, 287
 5-Hydroxydopamine, 191
 Hydroxyurea, as DNA inhibitor, 52
- Idoxuridine, 20
 Immediate early PRV proteins, 129–131, 134–135
 Immediate early PRV RNA, 122–123, 124–126, 127–129
 Immortalization assay, 275
 Immune adherence, 5
 Immune mechanisms, of reactivation, 202–203
 Immunoaffinity columns, 390–392
 Immunoglobulins, latency and, 194–195, 202–203
 Immunosuppression, HSV infections and, 20–21
 recurrent disease and, 218–219, 220–221
 Infection, symptomatic disease and, 7
 Infectious bulbar paralysis: *see* Aujeszky's disease
 Infectivity
 glycosylation and, 333, 375–376
 of virions, 331–336
 Influenza virus, 334, 357, 361
 Interferon, 203
 Intranuclear inclusions, PRV-induced, 120–121
 Intron, 52
 Isomerization, of genome, 146–148, 149
- Kaposi's varicella, 3, 20
 Keratitis, herpetic
 sex differences in, 223
 T cell activity in, 218
 Keratoconjunctivitis, 3, 18–20

- Lacrimal glands, HSV infection of, 181
- Langerhans cells, HSV recurrent infection and, 221
- Latency, of HSV, 12–14, 175–240
 - animal models of, 176
 - antigens in, 197
 - cell models of, 72
 - in central nervous system, 179–180
 - defective-interfering particles in, 195
 - dynamic state of, 195, 196
 - enzymes in, 197
 - evolutionary aspects of, 224–225
 - extraneural, 180–182
 - Fc receptors and, 194–195
 - ganglia, establishment in, 182–198
 - genome in, 191–192, 196, 203–204
 - immunoglobulins and, 194–195, 202–203
 - in latently infected cells, 188–190
 - in neurons, 176–180, 189–195, 203–205
 - peripheral lesions and, 176–179, 209–224
 - reactivation from, 176–179, 198–224
 - recurrence and, 175
 - mRNA in, 197–198
 - shedding and, 207
 - sites of, 176–182
 - specific genes in, 193–194
 - static state of, 195, 198
 - thymidine kinase and, 193–194
 - transcription during, 71–72
 - viral functions in, 195–198, 199
- Leucoagglutinin, 366
- Lumbosacral ganglia, latent HSV infection in, 177–178, 179, 181
- Lytic function, of HSV, 281
- Macrophage migration inhibition factor, 220
- Mapping
 - of DNA polymerase, 64–65
 - of HSV
 - glycoprotein genes, 316–318
 - polypeptides, 267–268
 - mRNA, 46
 - of HSV-1, 57–60
 - of PRV
 - genome, 157–158
 - polypeptides, 132–133
 - ribonucleotide reductase, 65
- Marker proteins, 45–47, 60, 62–63
- Marmoset, PRV infection in, 122
- Meningitis, 28
- β -Mercaptoethanol, 398–400
- Microneutralization, kinetic, 5
- Mink, PRV infection in, 122
- Mitomycin C, as DNA inhibitor, 52
- Monensin, glycosylation inhibition by, 329–330, 33, 375–376, 377
- Monoclonal antibodies
 - of CMV
 - glycoprotein characterization by, 386–392
 - immunoaffinity column analysis of, 390–392
 - of HSV, 110–111, 332
- Mouse
 - HSV infection in
 - latent, 179, 209
 - neurotropism of, 176
 - recurrent lesions of, 210–212, 213, 218
 - Mouse fibroblasts, oncogenic transformation in, 284–285
 - Mouse retrovirus, 71
- Mutation
 - HSV-1 Syn, 341–343
 - in oncogenic transformation, 287
 - of PRV, 154–157
- Myelitis, 28
- Nervous system, HSV infections in, 3, 7, 24–28, 176–180, 208
- Neurological disease, HSV-associated, 208
- Neurons, latent HSV infection in, 189–195
 - defective-interfering particles in, 195
 - Fc receptors in, 194–195
 - gene expression during, 72
 - genome structure and, 191–192
 - immune mechanisms of, 194–195, 202–203
 - physiological factors of, 203–205
 - productive infection, 190–191
 - reactivation of, 201–207
 - specific viral genes in, 193–194
- Newborn, HSV infections in, 21–24
 - incidence of, 21–22
 - symptoms of, 23–24
 - transmission of, 16, 22–23, 29
- Nuclear membrane biogenesis, in PRV, 153–154
- Nucleocapsids
 - of HSV, 68
 - of PRV, 108–110
 - capsid relationship, 151
 - formation, 151–153
 - membrane recognition by, 153–154
- Nucleoside analogs, 11, 16, 17

- Oligosaccharide chains: *see* Glycans
- Oncogenic transformation potential
- of adenovirus, 269, 279–280, 283–284, 286
 - assay of, 259, 273–274, 275–276; *see also* names of specific assays
 - of avian erythroblastosis virus, 284, 285
 - of avian leukosis virus, 268
 - of avian lymphoid leukosis virus, 284
 - of CMV, 257–258, 289–302
 - in cell culture, 290–292
 - DNA sequences of, 292–300
 - of HSV, 257–289, 300–302
 - antigenic markers of, 268
 - in cell culture, 259–261
 - defective virions in, 289
 - DNA sequences of, 263–266, 267, 268, 269–279, 280–282, 284–288, 289
 - genome fragment transformation, 272–281
 - genome homology of, 281–282
 - “hit-and-run” mechanism of, 277–278, 287
 - mutation and, 287
 - of polypeptides, 280–281
 - protein expression in, 266–270
 - thymidine kinase in, 262, 263–266
 - transformation frequency, 261–262
 - transformation mechanisms, 283–289
 - of papoviruses, 283
 - of polyomaviruses, 261–262, 278–279
 - of SV 40 virus, 261–262, 269, 287
- Oral herpetic infections, 3, 6–7, 11
- Oral therapy, 12
- Papillomaviruses, cervical cancer and, 33, 251, 252
- Papoviruses, oncogenic transformation potential of, 283
- Penetration, of host cell, 334–336
- Peripheral nervous system, latent HSV infections in, 176–179
- Phospholipid metabolism, in PRV-infected cells, 153
- Phosphonoacetic acid, DNA inhibition by, 384
- Phosphonoformate, as topical therapy, 18
- Pigeon, PRV infection in, 122
- Plasma membrane, glycoproteins in, 384–386
- Polyacrylamide gel electrophoresis of PRV proteins, 107, 108, 109, 110
- Polykaryocytes
 - PRV-induced, 120–121
 - HSV-induced, 340–345, 376–378
- Polyomaviruses, oncogenic transformation potential of, 258, 278–279
- transformation frequency, 261–262
- Polypeptides
- of HSV-infected cells
 - in oncogenic transformation, 266–270, 280–281
 - synthesis of, 326–331
 - of PRV-infected cells, 107–111
 - mapping of, 132–133
 - structural, 107–110
 - synthesis of
 - kinetics of, 326
 - regulation of, 327–328
 - mRNA synthesis and, 327–328
 - sequence of events in, 328–331
- Polysomes, disaggregation of, 53
- Pregnant women, genital herpetic infections in, 16, 22
- Pronase-digestion, of glycoproteins, 365, 368, 369, 370
- Prostaglandins, HSV infection recurrence and, 220–221, 222
- Protein(s)
- capsid, 68–70
 - cellular stress, 72
 - DNA-binding, 135–136
 - nucleocapsid, 68
 - of PRV, 107–111
 - early and late, 132
 - immediate early, 129–131, 134–135
 - polyacrylamide gel electrophoresis of, 107, 108, 109, 110
 - structural components of, 107–110
 - virus neutralization by, 110–111
- Protein kinase, PRV-associated, 110
- Protein markers: *see* Biological markers
- Protein synthesis
- in CMV-infected cells, 296–298
 - in HSV-infected cells, 53–54
 - in PRV-infected cells, 129–138
 - control of, 133, 158–159
 - DNA synthesis and, 130–131, 132
 - mapping of, 132–133
 - patterns of, 129–132
 - virion-associated inhibition of, 53–54
- PRV: *see* Pseudorabies virus
- Pseudorabies virus
- antigenic relationships of, 111
 - capsids of, 107–109
 - assembly of, 148–151
 - characteristics of, 105
 - DNA
 - cleavage of concatemeric form, 151–153
 - defective, 142

- Pseudorabies virus (*cont.*)
 DNA synthesis, 122–123, 125, 138–141
 inhibition of, 160
 mode of, 143–144
 origins of, 141–143
 freeze-drying of, 107
 genetic map of, 157–158
 genome of, 111–119
 functional identity of, 116
 homology of, 147, 160–161
 isomerization of, 146–148, 149
 mapping of, 115–116, 117, 157–158
 organization of, 154–158
 restriction endonuclease cleavage of, 115–116, 117
 sequence identity maintenance in, 144–146
 size and base composition of, 111
 strain variability of, 116, 118
 structure of, 112–115
 of vaccine strains, 118–119
 glycoproteins of, 136–137
 irradiation effects, 106–107
 macromolecular synthesis and, 158–160
 morphology of, 106
 mutant phenotypes of, 154–157
 nuclear membrane biogenesis of, 153–154
 nucleocapsids of, 108–110
 formation of, 151–153
 membrane recognition by, 153–154
 phospholipid metabolism and, 153
 protein kinase activity of, 110
 protein synthesis and, 129–138
 control of, 133, 158–159
 mapping of, 132–133
 patterns of, 129–132
 proteins, 107–111
 early and late, 132
 immediate early, 129–131, 134–135
 polyacrylamide gel electrophoresis of, 107, 108, 109, 110
 structural components of, 107–110
 virus neutralization by, 110–111
 replication of, 119–122
 cytopathic cellular effects of, 120–121
 growth cycle in, 119–120
 host range for, 121–122
 RNA synthesis of, 122–129
 early and late, 122–123, 125, 127–129
 immediate early, 122–123, 124–126, 127–129
 mRNA accumulation in, 126–129
 rRNA in, 159
 transcript characteristics in, 125–126
- Pseudorabies virus (*cont.*)
 RNA synthesis of (*cont.*)
 transcription of patterns in, 122–124
 transitions in, 124–125
 stability of, 106–107
 transmission of, experimental, 122
 virion
 adsorption, 139
 assembly of, 148–154
 defective, 120
 inverted repeats in genomes of, 145–146
 membrane protein removal and, 109–110
 polypeptides, 107–111
See also Aujeszky's disease
 Psychiatric disorders, HSV-associated, 208
- Rabbit
 latent HSV infections in, 179, 209
 neurotropism of, 176
 PRV infections in, 122
 Radiation, of PRV, 106–107
 Rat, PRV infection in, 122
 Reactivation
 definition of, 198
 of HVS infections, 198–224
 autonomic nervous system diseases, 208
 encephalitis, 208–209
 host factors in, 201–205
 immune mechanisms of, 202–203
 neuron in, 206–207
 psychiatric disorders, 208
 results of, 207–224
 viral factors in, 205–206
 Receptors, of HSV-infected cells
 C3b, 340
 Fc, 194–195, 202, 335, 339
 Recrudescence, 198
 Recurrence
 definition of, 198
 latency and, 175
 reinfection vs., 12–18
See also under specific viruses
 Reinfection, recurrence vs., 12–18
 Restriction endonuclease analysis
 of CMV DNA, 292–293
 of HSV marker proteins, 45–47
 of HSV-2 DNA, 265, 269–270
 of PRV DNA, 111, 113–118
 Retrovirus, 71
 Rhesus monkey, PRV infection in, 122
 Ribonucleotide reductase
 HSV-induced, 65
 PRV-induced, 137–138

- RNA
 CMV, 48
 Epstein-Barr virus, 48, 50
 HSV
 general properties of, 48
 in latency, 197-198
 mapping of, 46
 nuclear forms of, 48-50
 polypeptide synthesis and, 327-328
 HSV-1
 analysis of, 55-57
 high-resolution mapping of, 57-60
 PRV, 132, 133, 159-160
 early and late, 122-123, 125, 127-129
 immediate early, 122-123, 124-126, 127-129
 transcript characteristics, 125-126
 transcription patterns, 122-124
 transitions in, 124-125
 See also Transcription
 RNA polymerase, 122, 125, 203
 Rough endoplasmic reticulum,
 glycoprotein precursors and, 361-363
- Saliva, viral shedding in, 180-181
Salivary glands, HSV infections in, 181
Screening, virologic, 6-7
Secretions, viral shedding in, 6-7, 180-181
Semliki Forest virus, 334
Seroepidemiologic surveys
 of cervical cancer, 243-245
 of HSV infections, 5-6
Sezary's syndrome, 20
Shedding
 in body secretions, 6-7, 180-181
 latency and, 207
 in oral HSV infections, 6-7
Sheep, PRV infections in, 122
Sialic acid, in glycosylation, 363, 366, 367, 369
Simian virus 40, oncogenic transformation
 potential of, 258, 269, 287
 transformation frequency, 261-262
Sindbis virus, 357, 361, 362
Skin, HSV infections of, 3, 20
 latent, 180, 181
 recurrent, 214-217
Squamous cell carcinoma, 245
Stomatitis, herpetic, 3, 29
Structural proteins, transcription of, 68-70
Suid herpesvirus, 105
Sulfation, of glycoproteins, 324-325, 359
Swine
 latent HSV infections in, 209
 PRV infections in, 105, 162-163
- Symptomatic disease, infection and, 7
Syncytia: *see* Polykaryocytes
- T cell, 218, 219-220
Tears, viral shedding in, 180-181
Thymidine kinase, in HSV-infected cells,
 27, 197
 latency and, 193-194
 as transcript marker, 64
 transformational activity of, 262, 263-266
Topical therapy, 17-18
Transcription
 of adenovirus, 51
 of equine abortion virus, 51
 of HSV
 analysis of, 55-60
 biological markers for, 45-47, 60, 62-63
 blot surveys of, 54-55, 56-57
 DNA replication functions, 61, 64-66
 α genes, 60-61
 glycoproteins, 66-68
 interior promoters of, 88-89
 latency and, 71-72
 localization of, 54-55, 274
 morphological transformation genes,
 70-71
 multiple promoters of, 86-88
 related protein functions, 89-90
 specific genes in, 60-72
 splicing and, 89
 structural proteins, 68-70
 termination of, 86, 88
 of "typical" gene, 84-86
 units of, 72-86
 of PRV, 51
Transposons, 191-192
Trifluorothymidine, 20
Trigeminal ganglion, latent HSV infection
 in, 72, 176-177, 178, 180, 182, 196, 197
Trypsin, viral sensitivity to, 106
Tumor-associated antigens, 31-32, 245-248, 250, 251
Tunicamycin, glycosylation blockage by,
 323, 333, 374, 377
- Ultraviolet light, effect on recurrent
 infection, 221
- Vagina, latent HSV infection in, 181
Varicella zoster virus, 2
Varicella, Kaposi's, 3, 20
Vero cells, HSV in, 221

- Vesicular stomatitis virus, 321, 334, 357, 361
- Vidarabine, 20, 24, 26–27
- Viron(s)
- of CMV
 - contents of, 383
 - glycoproteins in, 384–386
 - of HSV
 - adsorption by, 334
 - defective, 289
 - egress of, 337–338
 - endocytosis of, 334–335
 - envelopment of, 336–337
 - infectivity of, 331–336
 - oncogenic transformation potential of, 258–261, 289
 - in protein synthesis inhibition, 53–54
- Viron(s) (*cont.*)
- of PRV
 - adsorption by, 139
 - assembly process of, 148–154
 - defective, 120
 - inverted repeats in, 145–146
 - membrane protein removal by, 109–110
 - Virion polypeptides, 107–111
 - Virion proteins, 143
 - Virulence, trypsin sensitivity and, 106
- Whitlow ulcer, 20
- Zoster virus: *see* Herpes zoster